SV Life Sciences and Novo A/S have provided £8m in a series-A round for ophthalmology company KalVista Pharmaceuticals.
This article is only available to subscribers to unquote.com. Subscribers just need to log in below for immediate access. Not a subscriber? Sign up now for immediate free trial access
Sign up
Free trial
Try unquote.com free for 2 weeks. A trial will give you access to the entire site.